| Literature DB >> 15003519 |
Seung-Hyun Ko1, Hyuk-Sang Kwon, Sung-Rae Kim, Sung-Dae Moon, Yu-Bae Ahn, Ki-Ho Song, Hyun-Sik Son, Bong-Yun Cha, Kwang-Woo Lee, Ho-Young Son, Sung-Koo Kang, Chung-Gyu Park, In-Kyu Lee, Kun-Ho Yoon.
Abstract
We evaluated whether ramipril, one of long-acting ACEIs, has a direct effect on pancreas islets in animal model of type 2 diabetes. OLETF rats were treated with ramipril for 24 weeks. We assessed the body weight, glucose tolerance, and the amount of islet fibrosis. RT-PCR and Western blot analysis of transforming growth factor-beta with its downstream signals were performed from the pancreas. Ramipril treatment remarkably reduced weight gain and the area under the curve of glucose. Islet fibrosis and the expression of TGF-beta with its downstream signal molecules were significantly reduced in the pancreas of ramipril-treated group than in control and paired-feeding group. These beneficial effects of ramipril might be related to the downregulation of TGF-beta and its downstream signals in OLETF rats. To our knowledge, this is the first report suggesting the potential effect of ramipril on the prevention of islet destruction by fibrosis in the animal model of type 2 diabetes mellitus.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15003519 DOI: 10.1016/j.bbrc.2004.02.023
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575